JP2005533064A - 2,5−ジ置換3−メルカプトペンタン酸 - Google Patents

2,5−ジ置換3−メルカプトペンタン酸 Download PDF

Info

Publication number
JP2005533064A
JP2005533064A JP2004513253A JP2004513253A JP2005533064A JP 2005533064 A JP2005533064 A JP 2005533064A JP 2004513253 A JP2004513253 A JP 2004513253A JP 2004513253 A JP2004513253 A JP 2004513253A JP 2005533064 A JP2005533064 A JP 2005533064A
Authority
JP
Japan
Prior art keywords
phenyl
substituted
hydroxy
itself
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004513253A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005533064A5 (enExample
Inventor
ポーラ,マグヌス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2005533064A publication Critical patent/JP2005533064A/ja
Publication of JP2005533064A5 publication Critical patent/JP2005533064A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/40Unsubstituted amino or imino radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004513253A 2002-06-14 2003-06-10 2,5−ジ置換3−メルカプトペンタン酸 Withdrawn JP2005533064A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201837A SE0201837D0 (sv) 2002-06-14 2002-06-14 Chemical compounds
PCT/SE2003/000970 WO2003106420A1 (en) 2002-06-14 2003-06-10 2,5-disubstituted 3-mercaptopentanoic acid

Publications (2)

Publication Number Publication Date
JP2005533064A true JP2005533064A (ja) 2005-11-04
JP2005533064A5 JP2005533064A5 (enExample) 2006-07-06

Family

ID=20288202

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004513253A Withdrawn JP2005533064A (ja) 2002-06-14 2003-06-10 2,5−ジ置換3−メルカプトペンタン酸

Country Status (28)

Country Link
US (1) US7572817B2 (enExample)
EP (1) EP1532111B1 (enExample)
JP (1) JP2005533064A (enExample)
KR (1) KR20050010051A (enExample)
CN (1) CN100415719C (enExample)
AR (1) AR040240A1 (enExample)
AT (1) ATE369342T1 (enExample)
AU (1) AU2003241260B2 (enExample)
BR (1) BR0311384A (enExample)
CA (1) CA2488606A1 (enExample)
CY (1) CY1107753T1 (enExample)
DE (1) DE60315471T2 (enExample)
DK (1) DK1532111T3 (enExample)
ES (1) ES2289297T3 (enExample)
IS (1) IS7609A (enExample)
MX (1) MXPA04012604A (enExample)
MY (1) MY160429A (enExample)
NO (1) NO20045051L (enExample)
NZ (1) NZ536814A (enExample)
PL (1) PL373883A1 (enExample)
PT (1) PT1532111E (enExample)
RU (1) RU2365583C2 (enExample)
SA (1) SA03240142B1 (enExample)
SE (1) SE0201837D0 (enExample)
TW (1) TW200401766A (enExample)
UA (1) UA78042C2 (enExample)
WO (1) WO2003106420A1 (enExample)
ZA (1) ZA200409955B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
GB0403864D0 (en) 2004-02-20 2004-03-24 Ucl Ventures Modulator
JP2008538107A (ja) 2005-03-18 2008-10-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 変異型cftrプロセシングの修正において活性を有する化合物及びその用途
JPWO2010050525A1 (ja) 2008-10-29 2012-03-29 大正製薬株式会社 TAFIa阻害活性を有する化合物
TR201901110T4 (tr) 2013-04-05 2019-02-21 Boehringer Ingelheim Int Empagliflozinin terapötik kullanımları.
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN113181161A (zh) 2013-04-18 2021-07-30 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
BR112015029667A2 (pt) 2013-06-10 2017-07-25 Sanofi Sa derivados de ureia macrocíclica como inibidores de tafia, sua preparação e seus usos como produtos farmacêuticos
MA46742A (fr) 2016-11-10 2019-09-18 Boehringer Ingelheim Int Composition pharmaceutique, méthodes de traitement et leurs utilisations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4687500A (en) * 1999-04-29 2000-11-17 Allergan Sales, Inc. Thromboxane ligands without blood clotting side effects
SE9901573D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds

Also Published As

Publication number Publication date
BR0311384A (pt) 2005-03-15
EP1532111B1 (en) 2007-08-08
CN1662504A (zh) 2005-08-31
CN100415719C (zh) 2008-09-03
ES2289297T3 (es) 2008-02-01
MY160429A (en) 2017-03-15
AR040240A1 (es) 2005-03-23
CA2488606A1 (en) 2003-12-24
ZA200409955B (en) 2006-08-30
KR20050010051A (ko) 2005-01-26
PL373883A1 (en) 2005-09-19
US20050176780A1 (en) 2005-08-11
TW200401766A (en) 2004-02-01
SE0201837D0 (sv) 2002-06-14
WO2003106420A1 (en) 2003-12-24
US7572817B2 (en) 2009-08-11
RU2004134563A (ru) 2005-07-20
MXPA04012604A (es) 2005-03-23
NO20045051L (no) 2005-01-13
AU2003241260A1 (en) 2003-12-31
IS7609A (is) 2004-12-22
DE60315471T2 (de) 2008-04-24
HK1077296A1 (en) 2006-02-10
ATE369342T1 (de) 2007-08-15
AU2003241260B2 (en) 2007-04-26
RU2365583C2 (ru) 2009-08-27
EP1532111A1 (en) 2005-05-25
SA03240142B1 (ar) 2007-07-31
UA78042C2 (en) 2007-02-15
DE60315471D1 (de) 2007-09-20
DK1532111T3 (da) 2007-10-22
PT1532111E (pt) 2007-09-25
CY1107753T1 (el) 2013-04-18
NZ536814A (en) 2006-11-30

Similar Documents

Publication Publication Date Title
KR100755152B1 (ko) 신규 화합물
JP2001508796A (ja) トロンビン阻害薬
JP2002516326A (ja) イミダゾピリジン系トロンビン阻害薬
JPH08502484A (ja) フィブリノゲンリセプタ拮抗剤
TWI568727B (zh) 磺醯基胺基吡咯啶酮衍生物,彼等之製造及治療應用
JP2005533064A (ja) 2,5−ジ置換3−メルカプトペンタン酸
JP2002525370A (ja) トロンビン阻害剤
KR20190026905A (ko) 모노시클릭 헤테로아릴 치환된 화합물
US7022695B2 (en) Thioether-substituted benzamides as inhibitors of Factor Xa
US6387911B1 (en) Pyrazinone thrombin inhibitors
US20030158218A1 (en) Thrombin inhibitors
JP2001517623A (ja) トロンビン阻害薬
JP2008501622A (ja) カルボキシペプチダーゼuの阻害が有用な疾患を治療するための環状アナベノペプチン型のペプチドの使用、新規アナベノペプチン誘導体、および、それらの中間体
EP1526131A1 (en) Aminoalkyl-pyrazinones and -pyridones as thrombin inhibitors
HK1077296B (en) 2,5-disubstituted 3-mercaptopentanoic acid
EP1655296A1 (en) Thrombin inhibitors
KR20080021145A (ko) 트롬빈 억제성 2-옥소-1,2,5,6-테트라히드로피리딘 유도체
EP1674464A1 (en) Novel thrombin inhibitors
MXPA06003914A (en) Thioether-substituted benzamides as inhibitors of factor xa

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060522

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090810